share_log

Altimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SEC announcement ·  Mar 27 16:15
Summary by Moomoo AI
Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.
Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more